Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics’ filings can run hundreds of pages, packed with clinical data, FDA milestones, and cash-burn details that directly shape valuation. If you have ever combed a 10-K just to confirm runway or scrolled EDGAR for lab-results buried in an 8-K, you know the challenge.
Stock Titan turns that complexity into clarity. Our AI digests every submission the moment it hits EDGAR, from the TScan Therapeutics quarterly earnings report 10-Q filing to sudden 8-K trial updates. Interactive summaries point to R&D expense trends, partnership terms, and risk-factor shifts so you can focus on decisions, not document hunting.
Need real-time sentiment? Follow TScan Therapeutics insider trading Form 4 transactions as they post. Alerts surface TScan Therapeutics executive stock transactions Form 4 minutes after insiders act, helping professionals monitor confidence ahead of material events. Curious how dilution risks evolve? Our platform flags S-3 shelves, at-the-market programs, and equity offerings the second they appear.
Key resources we map for you:
- Annual insight: TScan Therapeutics annual report 10-K simplified with AI-highlighted burn-rate tables and trial timelines.
- Quarterly pulse: AI-tagged metrics in each 10-Q for faster TScan Therapeutics earnings report filing analysis.
- Material events: TScan Therapeutics 8-K material events explained—from RMAT awards to clinical holds—in plain English.
- Governance focus: TScan Therapeutics proxy statement executive compensation summarized alongside peer med-tech benchmarks.
Whether you’re understanding TScan Therapeutics SEC documents with AI for due diligence or tracking TScan Therapeutics Form 4 insider transactions real-time, Stock Titan provides the comprehensive, continuously updated view you need—TScan Therapeutics SEC filings explained simply.
Dworak Leiden, reporting as an officer (Principal Accounting Officer) of TScan Therapeutics, Inc. (TCRX), filed an initial Form 3 reporting ownership of stock options granted by the company. The Form 3 reflects six option grants exercisable between 04/03/2032 and 01/02/2035 covering a total of 366,925 shares of Voting Common Stock with exercise prices ranging from $1.81 to $6.00. Vesting schedules are described for each grant, generally providing 25% vesting after one year followed by equal monthly vesting over 36 months, with certain tranches tied to service dates or shareholder approval. The filing date for the event is 08/14/2025 and the Form is signed by an attorney-in-fact on behalf of the reporting person.
Lynx1 Capital Management LP and Weston Nichols filed Amendment No.2 to a Schedule 13G reporting beneficial ownership of 7,857,347 shares of TScan Therapeutics voting common stock, representing 15.0% of the class. The percentage is calculated using 52,314,039 shares outstanding as of May 7, 2025, and the shares are directly held by Lynx1 Master Fund LP.
The cover data shows 0 shares as sole voting or dispositive power and 7,857,347 shares as shared voting and dispositive power. The filing is a Schedule 13G with a certification that the securities were not acquired to change or influence control. The statement is signed by Weston Nichols on behalf of Lynx1 and individually, dated 08/14/2025.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,350,000 shares of TScan Therapeutics Voting Common Stock issuable upon exercise of warrants. These shares represent 2.52% of the company's Voting Common Stock based on an aggregate of 52,314,039 shares outstanding used for the calculation. The filing shows shared voting and dispositive power over the 1,350,000 warrant‑issued shares and no sole voting or dispositive power.
This position is reported as holdings through Adage affiliates and reflects potential future dilution if the warrants are exercised; the reported amount is not currently held as sole-owned shares.
TScan Therapeutics reported results for the quarter ended June 30, 2025, reflecting continued investment in its TCR-T therapy pipeline and collaborations. Revenue for the quarter was $3.1 million ( $5.2 million for the six months), driven by research activity under the Amgen collaboration that included a $30 million upfront payment. R&D and G&A increased to $32.6 million and $9.1 million for the quarter, respectively, resulting in a quarterly net loss of $37.0 million (six-month net loss $71.1 million), or $0.28 per share for the quarter.
The company held $169.4 million in cash and cash equivalents and $48.7 million in marketable securities as of June 30, 2025 (totaling ~$218.0 million excluding restricted cash), which management says supports operations into the first quarter of 2027. Long-term debt included a SVB term loan with $32.5 million principal outstanding and an effective interest rate of 8.46%. The filing also highlights regulatory progress with multiple Phase 1 INDs and continued R&D expenditures, alongside disclosed risks and expected ongoing losses.
TScan Therapeutics announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025. The Current Report states the press release is furnished as Exhibit 99.1 and that the information is furnished, not filed, so it is not subject to Section 18 liability or automatically incorporated by reference into other filings. The filing identifies the company as an emerging growth company and confirms its common stock trades under the symbol TCRX on the Nasdaq Global Market. The report is signed on the company’s behalf by Chief Executive Officer Gavin MacBeath.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
